BiondVax Pharmaceuticals Ltd. (BVXV), a biopharmaceutical company, closed Friday’s regular trading session at $1.68 after gaining an increase of 1.20 percentage points. In the aftermarket trading session, however, BVXV stock has shown an abysmal performance. The stock was trading at $1.56 after plunging 7.14% at the last check. The poor performance could be attributed to the announcement that the company would host an investor conference on the 4th of April. The investor’s pessimism that BindoVax would not be able to achieve the desired outcome from the conference could be perceived to be the major reason behind the sharp decline.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investor & Analysts Webinar
On 31st March, BVXV announced that it would be hosting an analyst and investor webinar on the 4th of April. The company said that its CEO, Amir Reichman, would be discussing the business highlights of the last few months. They include the collaboration with Max Planck Institute for Multidisciplinary Sciences with regards to the nanosized antibody pipeline development project, as well as preparation to manufacture nanosized antibodies at the biologics manufacturing facility of the company in Jerusalem.
FY 2021 Results
On the 28th of March, BVXV announced the results for FY 2021. The total operating expense bore by the company during the year was $11.19 million, which included R&D expenses of $3.3 million, while MG&A expenses of $7.8 million. The financial expenses bore by the company during 2021 were $3.49 million. BindoVax suffered a comprehensive loss of $12.85 million during FY 2021. The basic and diluted loss per share for the year stood at $0.02.
BVXV CEO Commentary
Amir Reichman, while commenting on the results said that the company is satisfied with the results of fiscal 2021. Several strategic initiatives taken during the year are the epitome of the company’s policy of building a broad-based pipeline that could leverage the R&D capabilities of the company.
What’s in Store for BVXV?
Looking ahead, analysts are of the view that BVXV stock holds several negative signals at the moment. Hence, it is expected to perform weakly during the next couple of weeks. Therefore investors should take a careful decision regarding investment in BVXV stock.
